Johnson & Johnson will pay $4 billion less than it had originally agreed to acquire Guidant, the troubled maker of implantable heart devices, under a revised $21.5 billion deal announced yesterday.
The new agreement is an apparent acknowledgment by Guidant of how significantly its outlook has declined because of disclosures about product problems, device recalls, investigations and lawsuits.
